EPCORE DLBCL-2
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT05578976 ↗
- Active, not recruiting
- Genmab
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 4 | |
| Podcasts | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Epcoritamab; Cyclophosphamide; Rituximab; Vincristine; Doxorubicin; Prednisone
- Arms
- Epcoritamab and R-CHOP · Experimental
- R-CHOP and Rituximab · Experimental
- Enrollment
- 900 (estimated)
- Primary outcomes
- Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5
- Sponsor
- Genmab
- Start
- Feb 8, 2023
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05578976 · updated Sep 11, 2026